Menarini Group, in collaboration with NewAmsterdam Pharma Company NV, has reported positive preliminary results from the Phase 3 BROOKLYN clinical trial for obicetrapib. This study assessed the efficacy and safety of obicetrapib in adult patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL-C levels were not adequately controlled with current therapies. The results showed a significant reduction in LDL-C levels, meeting the primary endpoint of the study.
During the 52-week trial, obicetrapib demonstrated a 36.3% reduction in LDL-C at week 12 and a 41.5% reduction at week 52 compared to placebo. The treatment was well tolerated, with safety results comparable to placebo, making it a promising option for patients with HeFH.
“The data from the BROOKLYN trial confirmed the ability of obicetrapib to significantly reduce LDL-C in HeFH patients who are already on multiple lipid-lowering therapies,” said Stephen Nicholls, Director of the Monash Victorian Heart Institute. This is particularly noteworthy as HeFH affects 1 in 250 people worldwide and carries an increased risk of cardiovascular events.
Patients with high cholesterol often struggle to achieve guideline-recommended LDL-C levels despite available treatments. Katherine Wilemon, Founder and CEO of the Family Heart Foundation, expressed optimism about the results, highlighting the potential of obicetrapib as a new, effective oral option.
Elcin Barker Ergun, CEO of the Menarini Group, emphasized the importance of providing additional options for patients with cardiovascular disease. The positive outcomes of the BROOKLYN trial mark a significant milestone in the fight against cardiovascular diseases, especially for the HeFH community.
Obicetrapib is a novel CETP inhibitor being studied in multiple pivotal Phase 3 trials, including BROADWAY and PREVAIL, which are assessing its efficacy in reducing LDL-C levels and providing cardiovascular protection. The potential of obicetrapib to address the unmet needs of patients with metabolic diseases is promising, offering a safe and convenient lipid-lowering therapy option.
As a leading international pharmaceutical and diagnostics company, Menarini Group is dedicated to developing innovative solutions for areas of unmet medical need. With a focus on therapeutic areas such as cardiology, oncology, and infectious diseases, Menarini is committed to improving patient care worldwide.
For more information about the Menarini Group and its ongoing research efforts, please visit their official website. Stay tuned for further updates on the progress of obicetrapib and its potential impact on cardiovascular disease management.
Source link
